2 October 2024
Fusion Antibodies
plc
("Fusion"
or the "Company")
Block admission six monthly
return
Fusion Antibodies plc (AIM: FAB), specialists
in pre-clinical antibody discovery, engineering and supply for both
therapeutic drug and diagnostic applications, announces the following information in connection with its
block admission pursuant to AIM Rule 29 and Schedule Six of the AIM
Rules for Companies.
As of the date of this notification,
3,750 of the options over ordinary shares of 4 pence each in the
Company covered by the block admission announced by
the Company on 27 September 2021 (the "Block Admission")
remain outstanding. The Company has
applied for the Block Admission to be cancelled, and accordingly
the Block Admission will cease to exist with effect from 3 October
2024. The 3,750 options will remain outstanding.
|
Name of company:
|
Fusion Antibodies plc
|
|
Name of scheme:
|
Historic options, EMI and Unapproved
Employee Share Option Scheme, as announced on 27 September
2021
|
|
Period of return:
|
From 2 April 2024 to 1 October
2024
|
|
Number and class of securities not
issued under the scheme at the beginning of the period:
|
38,750 ordinary shares of 4 pence
each in the Company ("Ordinary Shares")
|
|
Number of securities issued under the
scheme during the period:
|
Nil
|
|
Number of options under the scheme
that have lapsed during the period:
|
Options over 35,000 Ordinary Shares
|
|
Balance under the scheme of
securities not yet issued at the end of the period:
|
3,750 Ordinary Shares
|
|
Number and class of securities
originally admitted and the date of admission:
|
917,083 Ordinary Shares on 27
September 2021
|
|
Contact name and telephone
number:
|
Stephen Smyth, Interim CFO via
Walbrook PR
+44 (0)20 7933 8780
|
Enquiries:
|
Fusion
Antibodies plc
|
www.fusionantibodies.com
|
|
Adrian Kinkaid, Chief Executive
Officer
Stephen Smyth, Chief Financial
Officer
|
Via Walbrook
PR
|
|
|
|
|
Fusion
Antibodies interactive investor hub
|
https://investorhub.fusionantibodies.com/
|
|
|
|
|
Allenby
Capital Limited
|
Tel: +44 (0) 20 3328
5656
|
|
James Reeve/Vivek Bhardwaj (Corporate
Finance)
Tony Quirke/Joscelin Pinnington (Sales and
Corporate Broking)
|
|
|
|
|
|
|
|
|
Shard Capital
Partners LLP
|
|
|
Damon Heath (Joint Broker)
|
Tel: +44 (0) 207 186
9952
|
|
|
|
|
|
|
|
Walbrook
PR
|
Tel:
+44 (0)20 7933 8780 or fusion@walbrookpr.com
|
|
Anna Dunphy
|
Mob: +44 (0)7876 741 001
|
|
|
|
About Fusion
Antibodies plc
Fusion is a Belfast based contract research
organisation ("CRO") providing a range of antibody engineering
services for the development of antibodies for both therapeutic
drug and diagnostic applications.
The Company's ordinary shares were admitted to
trading on AIM on 18 December 2017. Fusion provides a broad range
of services in antibody generation, development, production,
characterisation and optimisation. These services include antigen
expression, antibody production, purification and sequencing,
antibody humanisation using Fusion's proprietary
CDRx TM platform and the production of
antibody generating stable cell lines to provide material for use
in clinical trials. Since 2012, the Company has successfully
sequenced and expressed over 250 antibodies and successfully
completed over 200 humanisation projects and has an international,
blue-chip client base, which has included eight of the top 10
global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin
out from Queen's University Belfast. The Company's mission is to
enable pharmaceutical and diagnostic companies to develop
innovative products in a timely and cost-effective manner for the
benefit of the global healthcare industry. Fusion Antibodies
provides a broad range of services in antibody generation,
development, production, characterisation and
optimisation.
Fusion Antibodies growth strategy is based on
combining the latest technological advances with cutting edge
science to deliver new platforms that will enable Pharma and
Biotech companies get to the clinic faster, with the optimal drug
candidate and ultimately speed up the drug development
process.
The global monoclonal antibody
therapeutics market was valued at $186 billion in 2021 and is
forecast to surpass $445 billion in 2028, an increase at a CAGR of
13.2 per cent. for the period 2022 to 2028. Approximately 150
monoclonal antibody therapies are approved and marketed globally as
of June 2022 with the top four antibody drugs each having sales of
more than $3 bn in 2021.